Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers

Launched by INDUSTRIAL FARMACÉUTICA CANTABRIA, S.A. · Feb 21, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at the effects of a dietary supplement called CL-P24113a on hair growth in men aged 18 to 45 who have mild to moderate hair loss, known as androgenetic alopecia. The study will involve 45 participants, with some receiving the actual supplement and others receiving a placebo (a pill that does not contain the active ingredient) for six months. Participants will take one capsule daily, and the study will track hair growth through various measurements, as well as through surveys about their own experiences with hair loss.

To qualify for this study, participants must be male, between 18 and 45 years old, and have been diagnosed with mild to moderate hair loss. They should not have used any other hair treatments for at least 30 days before the study starts, and they will need to shave a small area of their scalp for the duration of the trial. Throughout the study, their health will be monitored closely to ensure safety. This trial aims to provide valuable information about whether this supplement can effectively promote hair growth and offer a safe alternative to existing hair loss treatments.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Written consent for LOPD compliance.
• • Written informed consent for study DC.506.36.117.
• • Gender: Male.
• • Age: Between 18 and 45 years.
• • Diagnosis of alopecia with low hair density, classified as mild to moderate (stages II, III, and IV on the Hamilton-Norwood scale).
• • Willingness to have a 1-2 cm² area shaved throughout the study period.
• • Last participation in a clinical study on hair health must have ended at least six months before the start of this study.
• • 30-day washout period without specific hair treatments (using a neutral shampoo).
• • No use of any other topical or oral hair treatments in the target area during the study period; if necessary, consultation with the principal investigator is required to evaluate continued study participation.
• Exclusion Criteria:
• • Individuals with gastrointestinal diseases (e.g., diabetes, gastritis, Crohn's disease, celiac disease, ulcers, intolerances, etc.).
• • Individuals with other physiological disorders (e.g., diabetes, hypertension, dyslipidemia) and/or gallstones.
• • Individuals undergoing medical treatment in the weeks prior to the study that may interfere with study assessments (as determined by the investigator), particularly those who are currently taking or have taken 5α-reductase inhibitors (Finasteride, Dutasteride, Minoxidil, etc.) within the last three months.
• • Individuals who have undergone hair restoration treatments at any point in their lives, including hair transplants, mesotherapy, or platelet-rich plasma (PRP) therapy.
• • Individuals following an atypical diet or planning to change their dietary routine during the study period.
• • Individuals enrolled in another clinical study with similar characteristics (as determined by the investigator) during the study period.
• • Individuals who are unable to fully understand the informed consent document or adhere to the study protocol.